Metsera (MTSR) Competitors $52.78 +0.26 (+0.50%) As of 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock MTSR vs. GMAB, SMMT, ASND, VTRS, RDY, MRNA, ROIV, QGEN, ELAN, and BBIOShould you be buying Metsera stock or one of its competitors? The main competitors of Metsera include Genmab A/S (GMAB), Summit Therapeutics (SMMT), Ascendis Pharma A/S (ASND), Viatris (VTRS), Dr. Reddy's Laboratories (RDY), Moderna (MRNA), Roivant Sciences (ROIV), Qiagen (QGEN), Elanco Animal Health (ELAN), and BridgeBio Pharma (BBIO). These companies are all part of the "pharmaceutical products" industry. Metsera vs. Its Competitors Genmab A/S Summit Therapeutics Ascendis Pharma A/S Viatris Dr. Reddy's Laboratories Moderna Roivant Sciences Qiagen Elanco Animal Health BridgeBio Pharma Genmab A/S (NASDAQ:GMAB) and Metsera (NASDAQ:MTSR) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, media sentiment, dividends, risk, analyst recommendations, institutional ownership, valuation and earnings. Is GMAB or MTSR more profitable? Genmab A/S has a net margin of 37.53% compared to Metsera's net margin of 0.00%. Genmab A/S's return on equity of 21.03% beat Metsera's return on equity.Company Net Margins Return on Equity Return on Assets Genmab A/S37.53% 21.03% 16.98% Metsera N/A N/A N/A Do analysts rate GMAB or MTSR? Genmab A/S currently has a consensus target price of $40.80, suggesting a potential upside of 24.69%. Metsera has a consensus target price of $55.75, suggesting a potential upside of 5.63%. Given Genmab A/S's stronger consensus rating and higher possible upside, equities analysts plainly believe Genmab A/S is more favorable than Metsera.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Genmab A/S 1 Sell rating(s) 2 Hold rating(s) 6 Buy rating(s) 2 Strong Buy rating(s) 2.82Metsera 1 Sell rating(s) 3 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.38 Do institutionals and insiders hold more shares of GMAB or MTSR? 7.1% of Genmab A/S shares are held by institutional investors. 1.5% of Genmab A/S shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. Which has stronger valuation and earnings, GMAB or MTSR? Genmab A/S has higher revenue and earnings than Metsera. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGenmab A/S$3.12B6.73$1.14B$1.9916.44MetseraN/AN/A-$209.13MN/AN/A Does the media prefer GMAB or MTSR? In the previous week, Genmab A/S had 15 more articles in the media than Metsera. MarketBeat recorded 19 mentions for Genmab A/S and 4 mentions for Metsera. Metsera's average media sentiment score of 0.85 beat Genmab A/S's score of 0.76 indicating that Metsera is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Genmab A/S 7 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Metsera 0 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryGenmab A/S beats Metsera on 12 of the 13 factors compared between the two stocks. Get Metsera News Delivered to You Automatically Sign up to receive the latest news and ratings for MTSR and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding MTSR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MTSR vs. The Competition Export to ExcelMetricMetseraMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$5.55B$3.40B$6.04B$10.51BDividend YieldN/A2.30%5.73%4.80%P/E RatioN/A22.9285.4427.36Price / SalesN/A268.92515.69196.40Price / CashN/A46.9537.5761.53Price / Book-21.4610.5512.426.82Net Income-$209.13M-$52.58M$3.32B$276.89M7 Day Performance-0.11%1.09%1.01%0.27%1 Month Performance54.28%16.09%10.75%8.31%1 Year PerformanceN/A18.41%76.20%35.60% Metsera Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MTSRMetseraN/A$52.78+0.5%$55.75+5.6%N/A$5.55BN/A0.0081GMABGenmab A/S4.2057 of 5 stars$33.56+4.5%$40.80+21.6%+38.4%$21.53B$3.26B16.862,682Trending NewsAnalyst ForecastAnalyst RevisionHigh Trading VolumeSMMTSummit Therapeutics2.964 of 5 stars$21.43+2.7%$31.29+46.0%+7.4%$15.50B$700K-21.22110Analyst UpgradeGap UpASNDAscendis Pharma A/S3.1962 of 5 stars$204.05+1.5%$244.36+19.8%+62.5%$12.38B$393.54M-39.541,017News CoverageAnalyst ForecastAnalyst RevisionVTRSViatris2.3836 of 5 stars$10.19+0.8%$10.40+2.1%-12.8%$11.88B$14.12B-3.5132,000News CoverageAnalyst ForecastRDYDr. Reddy's Laboratories2.7137 of 5 stars$14.17+0.7%$16.95+19.7%-11.6%$11.75B$3.81B21.4627,811News CoveragePositive NewsMRNAModerna4.26 of 5 stars$28.49+0.4%$41.81+46.8%-54.5%$11.08B$3.06B-3.785,800ROIVRoivant Sciences3.063 of 5 stars$16.17+1.2%$19.94+23.3%+38.5%$10.91B$29.05M-23.10860Insider TradeQGENQiagen4.3804 of 5 stars$46.83+1.3%$49.40+5.5%+10.8%$10.28B$2.04B27.675,765ELANElanco Animal Health2.78 of 5 stars$20.65+0.9%$18.33-11.2%+41.0%$10.17B$4.48B24.019,000Analyst RevisionBBIOBridgeBio Pharma4.1201 of 5 stars$52.86-0.8%$63.94+21.0%+119.2%$10.11B$235.81M-12.92400 Related Companies and Tools Related Companies GMAB Alternatives SMMT Alternatives ASND Alternatives VTRS Alternatives RDY Alternatives MRNA Alternatives ROIV Alternatives QGEN Alternatives ELAN Alternatives BBIO Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MTSR) was last updated on 10/15/2025 by MarketBeat.com Staff From Our PartnersURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredBitcoin grabs headlines, but smart money likes this tokenBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | SponsoredGold surges past $3,600 … but this has beat gold by 1,000xGold has surged past $3,600 an ounce — up 45% in the past year — but one veteran metals analyst says the real ...Weiss Ratings | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredArizona-made nanochips the new millionaire maker?George Gilder handed President Reagan the first microchip that helped create $6.5 trillion in wealth over the ...Banyan Hill Publishing | SponsoredBuy UBER immediatelyBULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Metsera Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Metsera With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
